Redwood City, CA9 days ago
As a key member of the Clinical Data Science, Analytics, and Systems (CDSAS) Leadership Team, the Executive Director will partner closely with Development, Clinical Development, Clinical Operations, Global Patient Safety, Regulatory Affairs, Medical Writing, and within Quantitative Science (Translational Medicine, Biostatistics, Statistical Programming) to ensure data strategies align with the needs of an evolving oncology pipeline. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.